No molnupiravir: ICMR team
The Hindu
It says drug is not of much benefit in COVID-19 treatment
The ICMR’s National Task Force for COVID-19 has decided against including in the Clinical Management Protocol for COVID-19 as of now, official sources said on Tuesday.
The experts of the task force cited safety concerns, and argued that Molnupiravir was not of much benefit in COVID treatment to arrive at the decision in a meeting held on Monday.
According to the Health Ministry, Molnupiravir is an antiviral drug that inhibits SARS-CoV-2 replication by viral mutagenesis. This anti-COVID pill got the Drug Regulator General of India’s approval on December 28 for restricted use in emergencies. Mutagenesis is a process by which the genetic information of an organism is changed by the production of mutation.